

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. TRIEBEL=2A		SERIAL NO. NOT YET ASSIGNED		
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT: Frederic TRIEBEL				
				FILING DATE: ON EVEN DATE HEREWITH				
FOREIGN PATENT DOCUMENTS (include at least document number, publication date and country)								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AA	0 385 909	05SE1990	EUROPE			XXXX	
	AB	96 20215	04JL1996	PCT			XXXX	
	AC	96 17874	13JE1996	PCT			XXXX	
	AD	89 02922	06AP1989	PCT			XXXX	
	AE	95 30750	16NO1995	PCT			XXXX	
	AF	0 394 827	31OC1990	EUROPE			XXXX	
	AG	91 10682	25JL1991	PCT				XXXX
	AH	96 04386	15FE1996	PCT			XXXX	
	AI	95 21528	17AU1995	PCT			XXXX	
	AJ	97 24132	10JL1997	PCT			XXXX	
	AK	90 01870	08MR1990	PCT			XXXX	

OTHER DOCUMENTS (include at least document number, publication date and country)		
AL	HUARD et al., "CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins, <u>Eur. J. Immunol.</u> , vol.25, pp.2718-2721, (1995)	
AM	MCKINNEY et al., "A simple, non-chromatographic procedure to purify immunoglobulins from serum and ascites fluid", <u>Journal of Immunological Methods</u> , vol.96 pp.271-278, (1987)	
AN	TIGHE et al., "Gene vaccination: plasmid DNA is more than just a blueprint", <u>IMMUNOLOGY TODAY</u> , vol.19, no.2, pp.89-97, (1998)	
AO	BRUNOQUEL et al., "Genomic Organization of the Human LAG-3/CD4 locus", <u>Immunogenetics</u> , vol.47, pp.96-98, (1997)	
AP	KOCH et al., "High Level IL-12 Production by Murine Dendritic Cells: Upregulation via MHC Class II and CD40 Molecules and Downregulation by IL-4 and IL-10", <u>J.Exp. Med.</u> , vol.184, pp.741-746, (1996)	
AQ	WADE et al. "Structural compartmentalization of MHC class II signaling function", <u>Immunology Today</u> , vol.14, no.11, pp.539-546, (1993)	
AR	PARDOLL et al., "Paracrine Cytokine Adjuvants in Cancer Immunotherapy", <u>Annu. Rev. Immunol.</u> , vol.13, pp.399-415, (1995)	
AS	RESTIFO et al., "Biology of Cellular Immune Response", <u>Biological Therapy of Cancer</u> , pp.3-37, (1995)	
AT	COSGROVE et al., "Mice Lacking MHC Class II Molecules", <u>Cell</u> , vol.66, pp.1051-1066, (1991)	
AU	TAKEBE et al., "SR α Promoter: an Efficient and Versatile Mammalian cDNA Expression System Composed of the Simian Virus 40 Early Promoter and the R-U5 Segment of Human T-cell Leukemia Virus Type 1 Long Terminal Repeat", <u>Molecular and Cellular Biology</u> , vol.8, no.1, pp.466-472, (1988)	

	AV	CHEN et al., "Costimulation of Antitumor Immunity by the B7 Counterreceptor for the T Lymphocyte Molecules CD28 and CTLA-4", <u>CELL</u> , vol.71, pp.1093-1102, (1992)
	AW	ANGEVIN et al., "Analysis of T-cell Immune Response in Renal Cell Carcinoma: Polarization to Type 1-Like Differentiation Pattern, Clonal T-cell Expansion and Tumor-Specific Cytotoxicity", <u>Int. J. Cancer</u> , vol.72, pp.431-440, (1997)
	AX	MIYAZAKI et al., "Independent Modes of Natural Killing Distinguished in Mice Lacking Lag3", <u>SCIENCE</u> , vol.272, pp.405-408, (1996)
	AY	HUARD et al., "T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding", <u>Eur. J. Immunol.</u> , vol.26, pp.1180-1186, (1996)
	AZ	HUARD et al., "Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes", <u>Eur. J. Immunol.</u> , vol.24, pp.3216-3221, (1994).
	BA	HUARD et al., "Characterization of the major histocompatibility complex class II binding site on LAG-3 protein", <u>Proc. Natl. Acad. Sci.</u> , vol.94 pp.5744-5749, (1997)
	BB	HUARD et al., "Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand", <u>Immunogenetics</u> , vol.39, pp.213-217, (1994)
	BC	TRIEBEL et al., "LAG-3 a Novel Lymphocyte Activation Gene Closely Related to CD4", <u>J. Exp.Med.</u> , vol.171, pp1393-1405, (1990)
	BD	HUARD et al., "T cell MHC Class II Molecules Downregulated T Cell Proliferation following LAG-3 Binding", <u>Eur. J. Immunol.</u> , vol.25, pp.2718-2721, (1995)
	BE	BAIXERAS et al., "Characterization of the Lymphocyte Activation Gene 3-Encoded Protein. A New Ligand for Human Leukocyte Antigen Class II Antigens", <u>J. Exp. Med.</u> , vol.176, pp.327-337, (1992).
	BF	WAHREN, "Gene Vaccines", <u>IMMUNOTECHNOLOGY</u> , vol.2, pp.77-83, (1996)
	BG	DRANOFF et al., "Prospects for the Immunotherapy of Cancer Using Genetically Modified Tumors Cells", <u>Klinische Pharmakologie</u> , vol.9, pp.22-29, (1992)
	BH	WILLIAMS et al., "Genetic Infection Induces Protective In Vivo Immune Responses", <u>DNA AND CELL BIOLOGY</u> , vol.12, no.8, pp.675-683, (1993)
	BI	HUARD et al., "Cellular expression and tissue distribution of the Human LAG-3-encoded protein, an MHC Class II ligand", <u>IMMUNOGENETICS</u> , vol.39, pp.213-217, (1994)
	BJ	FAURE et al., "Soluble polypeptide fractions of the LAG-3 protein", NCBI, PubMed Database, Accession Number AAE27624 (2000)
	BK	LAZAR et al., "Transforming growth factor alpha: Mutation of Aspartic Acid 47 and Leuine 48 results in different biological activities", <u>Molecular and Cellular Biology</u> , 8:1247-1252 (1988)
	BL	BURGESS et al., "Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue", <u>Journal of Cellular Biology</u> , 111 (1990)
	BM	KANG et al., "Immunization with soluble CD4-gp 120 complex preferentially induces neutralizing anti-human immunodeficiency virus type I antibodies", <u>Journal of Virology</u> , 68(9)5854-5862 (1994)
	BN	PELIKAN et al., "Autoimmune mechanisms in the pathogenesis of neurologic paraneoplastic diseases (Abstract only), Bratislavske Lekarske Listy, 98(6)335-338 (1997)
	BO	ABBAS et al., Cellular and Molecular Immunology, 153-155 (1991)
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if reference considered. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.		